Seven months after suspending sales of its weight loss balloon in France due to safety concerns, Allurion’s products are back on sale in the country. In August 2024, the US company agreed to ...

announced its intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 agonists. The study will focus on combination use of the Allurion Balloon with lower dose ...

The Allurion Balloon, a non-surgical gastric balloon ... having held various leadership positions in the medical device industry. These are recent developments in Allurion's ongoing efforts ...

Allurion Technologies (ALUR) “announced that it has received two Issue Notifications from the U.S. Patent and Trademark Office dated February ...

Allurion Technologies ... loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The company was founded on January 25, 2023 and is ...

Talking to Medical Device Network ... Unlike other approaches, Allurion’s balloon does not require surgery, endoscopy, or anaesthesia. After around four months, the balloon releases the liquid ...

The study will focus on combination use of the Allurion Balloon with lower dose GLP-1s with the goal of demonstrating improved long-term tolerability and adherence to GLP-1 therapy. Previous ...

ALUR), a medical device company with a market capitalization of $17.7 million focused on addressing obesity, announced today its plan to conduct a clinical study on the combined use of the Allurion ...